Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

https://doi.org/10.17749/2070-4909.2017.10.1.003-010

Full Text:

Abstract

The aim of this study was to identify the most effective (in the clinical and pharmacoeconomic aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory to radioactive iodine in patients – residents of the Russian Federation.

Materials and Methods. The budget impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year period. The “cost-effectiveness” analysis was performed to compare the use of lenvatinib 15.28 mg/day, sorafenib 651 mg/day (after dose reduction), and chemotherapeutic agents. As part of the budget impact analysis (BIA), two scenarios were simulated: 1. DTC treatment using sorafenib and the chemotherapeutic agents (CTA);2. In some patients, the sorafenib + CTA therapy has been replaced with lenvatinib. The only parameter analyzed in this model was the drug cost. In the BIA, the impact of scenario 2 on the entire budget reserved for the thyroid cancer treatment was evaluated.

Results. Lenvatinib proved an effective agent (with a manageable safety profile) to be used in monotherapy of DTC refractory to radioactive iodine. According to the BIA, the introduction of lenvatinib had virtually no effect on the cost of thyroid cancer treatment. Using the “progression free survival” parameter, the cost-effectiveness ratio (CER) showed that the annual cost of effective treatment of DTC refractive to radioactive iodine with sorafenib or lenvatinib was 7 285 716.92 rubles or 3 368 077.62 rubles, respectively.

About the Authors

M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health Russian Federation
Russian Federation

Frolov Maxim Yurievich – PhD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department. 

Address: pl. Pavshikh Bortsov, 1, g. Volgograd, Russia, 400131



V. A. Rogov
Volgograd State Medical University of the Ministry of Health Russian Federation
Russian Federation

Rogov Vladimir Alexandrovich – candidate of pharmaceutical sciences of management and economics of pharmacy, medical and pharmaceutical merchandising department. 

Address: pl. Pavshikh Bortsov, 1, g. Volgograd, Russia, 400131



References

1. Kaprin A.D. Malignant neoplasms in Russia in 2014 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2014 g. (zabolevaemost’ i smertnost’) (in Russian)] / A.D. Kaprin, V.V. Starinskii, G.V. Petrovskaya. M. 2016; 250 s.

2. Kaprin A.D. State of cancer care in Russia in 2015 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 godu (in Russian)] / A.D. Kaprin, V.V. Starinskii, G.V. Petrovskaya. M. 2015; 236 s.

3. Frolov M.Yu., Rogov V.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 1: 23-31.

4. Alieva S.B. Clinical practice guidelines for the diagnosis and treatment of thyroid cancer [Klinicheskie rekomendatsii po diagnostike i lecheniyu raka shchitovidnoi zhelezy (in Russian)] / S.B. Alieva, Yu.V. Alymov, A.M. Mudunov i dr. M. 2014; 27 s.

5. Rumyantsev P.O. Klinicheskaya i eksperimental’naya tireoidologiya. 2015; 11 (2): 25-32.

6. Brown R. L., J.A. de Souza, Cohen E.  E.W. Thyroid Cancer. Burden of Illness and Management of Disease. Journal of Cancer. 2011; 2: 193-199.

7. Cabanillas M.  E., Habra M.A. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan.; 42: 47-55. DOI:10.1016–j.ctrv.2015.11.003. Epub 2015 Dec 2.

8. Mudunov A.M., Rumyantsev P.O., Podvyaznikov S.O. i dr. Opukholi golovyi shei. 2015; 5 (3): 59-63.

9. Brose M.S., Nutting C.M., Jarzab B. et al. sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384 (9940): 319-328.

10. Yagudina R. I. Farmakoekonomika: Teoriya i praktika. 2011; 4 (2): 9-12.

11. Balykina Yu.  E., Kolbin A.S. Farmakoekonomika: Teoriya i praktika. 2013; 6 (4). URL: http://cyberleninka.ru/article/n/ispolzovanienepryamyh-sravneniy-pri-provedenii-farmakoekonomicheskoyekspertizy.pdf. Accessed: 12.01.16.

12. Goryainov S.V., Rebrova O.Yu. Pediatricheskaya farmakologiya. 2012; 9 (2): 6-9.

13. Bucher H.C., Gordon H.G., Lauren E.G. et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Clinical Epidemiology. 1997; 50 (6): 683691.

14. Schlumberger M., Tahara M., Wirth L. et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. The New England Journal of Medicine. 2015; 621-630.

15. Medical statistics. Calculation of odds ratios with 95% confidence interval. (Online calculator) (in Russian). URL: http://medstatistic.ru/calculators/calcodds.html. Accessed: 12.01.2017.

16. Elliot M., Larson B., Kazi D.S. Thresholds for the costeffectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93: 118-124.

17. Fordham B.A., Kerr C. L., de Freitas H.M. et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015 Nov 3; (9): 1561-1572. DOI:10.2147/PPA.S90425.

18. Frampton J.  E. Lenvatinib: A Review in Refractory Thyroid Cancer. Target Oncol. 2016 Feb; 11 (1): 115-22. DOI:10.1007/s11523015-0416-3.

19. Yagudina R.I., Kulikov A.Yu., Metelkin I.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2012; 4: 3-8.


For citation:


Frolov M.Y., Rogov V.A. EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(1):3-10. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.1.003-010

Views: 312


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)